Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management

Supportive Care in Cancer

Volumn 24, Issue 4, 2016, Pages 1689-1695

  Le Moigne, Marie ^a,b   Saint Jean, Mélanie ^a,b   Jirka, Adam ^a   Quéreux, Gaëlle ^a,b   Peuvrel, Lucie ^a,b   Brocard, Anabelle ^a,b   Gaultier, Aurélie ^a   Khammari, Amir ^a,b   Darmaun, Dominique ^a   Dréno, Brigitte ^a,b,c  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c Dermato cancerology Unit   (France)

Author keywords

Dysgeusia; Malnutrition; Nutritional management; Vismodegib; Weight loss

Indexed keywords

VISMODEGIB; ZINC; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HUMAN; MALE; MALNUTRITION; MULTICENTER STUDY; NUTRITIONAL ASSESSMENT; NUTRITIONAL COUNSELING; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCREENING; SIDE EFFECT; UNIVERSITY HOSPITAL; WEIGHT REDUCTION; ZINC BLOOD LEVEL; CARCINOMA, BASAL CELL; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COHORT STUDIES; DYSGEUSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDINES; SKIN NEOPLASMS; WEIGHT LOSS;

EID: 84959147040     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2932-1     Document Type: Article

References (22)

1. Xie J, Murone M, Luoh SM et al (1998) Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391:90–92. doi:10.1038/34201
2. Sekulic A, Migden MR, Oro AE et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171–2179. doi:10.1056/NEJMoa1113713
3. Tang JY, Mackay-Wiggan JM, Aszterbaum M et al (2012) Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:2180–2188. doi:10.1056/NEJMoa1113538
4. Chang ALS, Solomon JA, Hainsworth JD et al (2014) Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70:60–69. doi:10.1016/j.jaad.2013.09.012
5. Basset-Seguin N, Hauschild A, Grob J-J et al (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. doi:10.1016/S1470-2045(15)70198-1
6. Baker JP, Detsky AS, Wesson DE et al (1982) Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med 306:969–972. doi:10.1056/NEJM198204223061606
7. Guigoz Y, Vellas BJ (1997) Malnutrition in the elderly: the Mini Nutritional Assessment (MNA). Ther Umsch Rev Thérapeutique 54:345–350
8. Thibault R, Goujon N, Le Gallic E et al (2009) Use of 10-point analogue scales to estimate dietary intake: a prospective study in patients nutritionally at-risk. Clin Nutr 28:134–140. doi:10.1016/j.clnu.2009.01.003
9. Chren M-M (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30:231–236. doi:10.1016/j.det.2011.11.003
10. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
11. National Cancer Institute. Common terminology criteria for adverse events v4.0, NCI, NIH, DHHS. May 29, 2009. NIH publication # 09-7473
12. Schroll M, Jørgensen L, Osler M, Davidsen M (1993) Chronic undernutrition and the aged. Proc Nutr Soc 52:29–37
13. Abbasi AA, Rudman D (1994) Undernutrition in the nursing home: prevalence, consequences, causes and prevention. Nutr Rev 52:113–122
14. Sánchez-Lara K, Sosa-Sánchez R, Green-Renner D et al (2010) Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 9:15. doi:10.1186/1475-2891-9-15
15. Yang H, Cong W-N, Yoon JS, Egan JM (2015) Vismodegib, an antagonist of Hedgehog signaling, directly alters taste molecular signaling in taste buds. Cancer Med 4:245–252. doi:10.1002/cam4.350
16. Berteretche MV, Dalix AM, d’ Ornano AMC et al (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12:571–576. doi:10.1007/s00520-004-0589-2
17. Heckmann SM, Hujoel P, Habiger S et al (2005) Zinc gluconate in the treatment of dysgeusia—a randomized clinical trial. J Dent Res 84:35–38
18. Najafizade N, Hemati S, Gookizade A et al (2013) Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: a randomized placebo-controlled trial. J Res Med Sci 18:123–126
19. Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087. doi:10.1007/s00520-010-0902-1
20. Tupe RP, Chiplonkar SA (2009) Zinc supplementation improved cognitive performance and taste acuity in Indian adolescent girls. J Am Coll Nutr 28:388–396
21. Stewart-Knox BJ, Simpson EEA, Parr H et al (2008) Taste acuity in response to zinc supplementation in older Europeans. Br J Nutr 99:129–136. doi:10.1017/S0007114507781485
22. Dummer R Basset-Seguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. 2015 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/144375-156. Accessed 28 Jul 2015.